Safety and effectiveness of dabigatran vs rivaroxaban in nonvalvular atrial fibrillation patients at nutritional risk.
L, L., H, L., G, A., J, Y., Z, Z., T, Y., B, S., L, Z., H, Q., & S, L. (2026). Safety and effectiveness of dabigatran vs rivaroxaban in nonvalvular atrial fibrillation patients at nutritional risk.. Research and practice in thrombosis and haemostasis. https://doi.org/10.1016/j.rpth.2026.106865
L L, H L, G A, J Y, Z Z, T Y, et al. Safety and effectiveness of dabigatran vs rivaroxaban in nonvalvular atrial fibrillation patients at nutritional risk.. Research and practice in thrombosis and haemostasis. 2026; doi: 10.1016/j.rpth.2026.106865
L L, H L, G A, et al. Safety and effectiveness of dabigatran vs rivaroxaban in nonvalvular atrial fibrillation patients at nutritional risk.[J]. Research and practice in thrombosis and haemostasis. 2026. DOI: 10.1016/j.rpth.2026.106865.
@article{l2026,
author = {Liu L and Liu H and Aa G and Yang J and Zhang Z and Yang T and Sun B and Zuo L and Qin H and Liu S},
title = {Safety and effectiveness of dabigatran vs rivaroxaban in nonvalvular atrial fibrillation patients at nutritional risk.},
journal = {Research and practice in thrombosis and haemostasis},
year = {2026},
doi = {10.1016/j.rpth.2026.106865},
note = {PMID: 42620299},
}
TY - JOUR AU - Liu L AU - Liu H AU - Aa G AU - Yang J AU - Zhang Z AU - Yang T AU - Sun B AU - Zuo L AU - Qin H AU - Liu S TI - Safety and effectiveness of dabigatran vs rivaroxaban in nonvalvular atrial fibrillation patients at nutritional risk. T2 - Research and practice in thrombosis and haemostasis PY - 2026 DO - 10.1016/j.rpth.2026.106865 AN - PMID:42620299 ER -
BACKGROUND: Malnutrition is a prevalent comorbidity in nonvalvular atrial fibrillation (NVAF), yet comparative evidence on oral anticoagulants in this vulnerable population is scarce. OBJECTIVES: We aimed to compare the safety and effectiveness of dabigatran with those of rivaroxaban in NVAF patients at nutritional risk. METHODS: This new-user, active-comparator cohort study utilized data from the Tianjin Health and Medical Data Platform (2015-2020). We identified 10,658 NVAF patients (dabigatran n = 1819; rivaroxaban n = 8839) at nutritional risk, defined as a Prognostic Nutritional Index score ≤50. Multivariable Cox proportional hazards models were used to compare the risks of intracranial hemorrhage (ICH), gastrointestinal bleeding, ischemic stroke, and all-cause mortality over a maximum 3-year follow-up. Extensive sensitivity analyses were performed to ensure the robustness of the findings. RESULTS: The incidence of ICH was significantly lower in the dabigatran group compared with the rivaroxaban group (0.55% vs 1.27%; hazard ratio [HR], 0.42; 95% CI, 0.22-0.80). This lower risk was particularly evident in patients receiving low-dose regimens (HR, 0.33; 95% CI, 0.16-0.69) and was consistent in short-term analyses. There were no significant differences between the 2 groups in the risks of gastrointestinal bleeding (HR, 0.99; 95% CI, 0.72-1.35), ischemic stroke (HR, 1.06; 95% CI, 0.86-1.31), or all-cause mortality (HR, 0.93; 95% CI, 0.80-1.09). CONCLUSION: In NVAF patients at nutritional risk, dabigatran was associated with a lower risk of ICH compared with rivaroxaban, without compromising effectiveness.